Literature DB >> 10940316

Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.

M P Boland1, K A Fitzgerald, L A O'Neill.   

Abstract

Topoisomerase II is a target for a number of chemotherapeutic agents used in the treatment of cancer. Its essential physiological role in modifying the topology of DNA involves the generation of transient double-strand breaks. Anti-cancer drugs, such as mitoxantrone, that target this enzyme interrupt its catalytic cycle and give rise to persistent double strand breaks, which may be lethal to a cell. We investigated the role of such lesions in signaling the activation of the transcription factor nuclear factor kappaB (NFkappaB) by this drug. Mitoxantrone activated NFkappaB and stimulated IkappaBalpha degradation in the promyelocytic leukemia cell line HL60 but not in the variant cells, HL60/MX2 cells, which lack the beta isoform of topoisomerase II and express a truncated alpha isoform that results in an altered subcellular distribution. Treatment of sensitive HL60 cells with mitoxantrone led to a depletion of both isoforms, suggesting the stabilization of transient DNA-topoisomerase II complexes. This depletion was absent in the variant cells, HL60/MX2. Activation of caspase 3 by mitoxantrone was also impaired in the HL60/MX2 cells. NFkappaB activation in response to tumor necrosis factor and bleomycin, the latter causing topoisomerase II-independent DNA damage, was intact in both cell lines. An inhibitor rather than a poison of topoisomerase II, Imperial Cancer Research Fund 187 (ICRF 187) the mechanism of which does not involve the generation of double strand breaks, did not activate NFkappaB, nor did it induce apoptosis in parental HL60 cells. However, ICRF 187 protected against IkappaB degradation in parental HL60 cells in response to mitoxantrone. This protection was also shown with another topoisomerase II inhibitor, merbarone, which is structurally and functionally distinct from ICRF 187. Their effects were specific, as neither protected against tumor necrosis factor-stimulated IkappaB degradation. The poisoning of topoiso- merase II with resultant DNA damage is therefore a critical signal for NFkappaB activation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940316     DOI: 10.1074/jbc.275.33.25231

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Functional analysis of the human CDC5L complex and identification of its components by mass spectrometry.

Authors:  P Ajuh; B Kuster; K Panov; J C Zomerdijk; M Mann; A I Lamond
Journal:  EMBO J       Date:  2000-12-01       Impact factor: 11.598

2.  Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients.

Authors:  A Chan; F X Weilbach; K V Toyka; R Gold
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

3.  Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.

Authors:  Anna M Azarova; Yi Lisa Lyu; Chao-Po Lin; Yuan-Chin Tsai; Johnson Yiu-Nam Lau; James C Wang; Leroy F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

Review 4.  [Mitoxanthrone in the therapy of multiple sclerosis].

Authors:  B C Kieseier; R Gold; H-P Hartung
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

Review 5.  Immunogenic cell death and DAMPs in cancer therapy.

Authors:  Dmitri V Krysko; Abhishek D Garg; Agnieszka Kaczmarek; Olga Krysko; Patrizia Agostinis; Peter Vandenabeele
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

6.  Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha.

Authors:  J van der Heijden; M C de Jong; B A C Dijkmans; W F Lems; R Oerlemans; I Kathmann; C G Schalkwijk; G L Scheffer; R J Scheper; G Jansen
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

7.  Mitoxantrone impairs proteasome activity and prompts early energetic and proteomic changes in HL-1 cardiomyocytes at clinically relevant concentrations.

Authors:  Vera Marisa Costa; João Paulo Capela; Joana R Sousa; Rute P Eleutério; Patrícia R S Rodrigues; José Luís Dores-Sousa; Rui A Carvalho; Maria Lourdes Bastos; José Alberto Duarte; Fernando Remião; M Gabriela Almeida; Kurt J Varner; Félix Carvalho
Journal:  Arch Toxicol       Date:  2020-09-07       Impact factor: 5.153

Review 8.  DNA topoisomerase-targeting chemotherapeutics: what's new?

Authors:  Selma M Cuya; Mary-Ann Bjornsti; Robert C A M van Waardenburg
Journal:  Cancer Chemother Pharmacol       Date:  2017-05-20       Impact factor: 3.288

9.  The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1.

Authors:  Min-Kyoung Kim; Yoon-Kyung Jeon; Jong-Kyu Woo; Yun Choi; Dae-Han Choi; Yeul-Hong Kim; Chul-Woo Kim
Journal:  Mol Cancer       Date:  2011-08-16       Impact factor: 27.401

10.  Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells.

Authors:  S Hövelmann; T L Beckers; M Schmidt
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.